LY353381 x HCl: an improved benzothiophene analog with bone efficacy complementary to parathyroid hormone-(1-34).

Sato M, Zeng GQ, Rowley E, Turner CH

Endocrinology1 Nov 1998Cited by 32 (Europe PMC)

PMID9794476DOI10.1210/endo.139.11.6307PepBankPUB-09794476

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

5 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, PTH had no effect on body weight.
In plain wordsIn ovariectomized rats, PTH did not affect body weight.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeBody weight
Study
Ratn: not reported in source
Ovariectomized osteopenic rats
Outcome group
Body weight · Metabolic and weight
Studied dose
10 microg/kg · 90 daysAs given in this study (Rat).
Source sentences
Summary
PTH at 10 microg/kg had no effect on body weight or uterine weight, but significantly increased bone mass to beyond those in sham-operated controls, baseline controls, and groups receiving other individual treatments at both axial and appendicular sites.
3 context sentences(design, population, supporting numbers)
Summary · context
The effects of LY353381 x HCl on bones, body weight, and uterine weight were evaluated in 7-month-old rats with osteopenia that was induced by ovariectomizing animals for 1 month before initiation of treatment with several agents individually, in combination, or in sequence.
Summary · context
LY353381 x HCl was administered daily by itself for 90 days, in combination with the amino-terminal fragment of PTH-(1-34) (PTH) for 90 days, or sequentially after PTH when PTH was discontinued after 45 days of treatment.
Summary · context
Additionally, comparisons were made of animals treated with PTH alone, 17alpha-ethynyl estradiol alone, equine estrogens (Premarin) alone, raloxifene alone, or combinations of PTH and equine estrogens or raloxifene.
Report a problemFND-0979447601
02AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, PTH had no effect on uterine weight.
In plain wordsIn ovariectomized rats, PTH did not affect uterine weight.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeUterine weight
Study
Ratn: not reported in source
Ovariectomized osteopenic rats
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
10 microg/kg · 90 daysAs given in this study (Rat).
Source sentences
Summary
PTH at 10 microg/kg had no effect on body weight or uterine weight, but significantly increased bone mass to beyond those in sham-operated controls, baseline controls, and groups receiving other individual treatments at both axial and appendicular sites.
3 context sentences(design, population, supporting numbers)
Summary · context
The effects of LY353381 x HCl on bones, body weight, and uterine weight were evaluated in 7-month-old rats with osteopenia that was induced by ovariectomizing animals for 1 month before initiation of treatment with several agents individually, in combination, or in sequence.
Summary · context
LY353381 x HCl was administered daily by itself for 90 days, in combination with the amino-terminal fragment of PTH-(1-34) (PTH) for 90 days, or sequentially after PTH when PTH was discontinued after 45 days of treatment.
Summary · context
Additionally, comparisons were made of animals treated with PTH alone, 17alpha-ethynyl estradiol alone, equine estrogens (Premarin) alone, raloxifene alone, or combinations of PTH and equine estrogens or raloxifene.
Report a problemFND-0979447602
03AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, PTH increased axial and appendicular bone mass beyond sham-operated controls.
In plain wordsIn ovariectomized rats, PTH increased spine and limb bone mass beyond sham-operated controls.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseAxial and appendicular bone mass versus sham
Study
Ratn: not reported in source
Ovariectomized osteopenic rats
Comparator
Sham-operated controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
10 microg/kg · 90 daysAs given in this study (Rat).
Source sentences
Summary
PTH at 10 microg/kg had no effect on body weight or uterine weight, but significantly increased bone mass to beyond those in sham-operated controls, baseline controls, and groups receiving other individual treatments at both axial and appendicular sites.
3 context sentences(design, population, supporting numbers)
Summary · context
The effects of LY353381 x HCl on bones, body weight, and uterine weight were evaluated in 7-month-old rats with osteopenia that was induced by ovariectomizing animals for 1 month before initiation of treatment with several agents individually, in combination, or in sequence.
Summary · context
LY353381 x HCl was administered daily by itself for 90 days, in combination with the amino-terminal fragment of PTH-(1-34) (PTH) for 90 days, or sequentially after PTH when PTH was discontinued after 45 days of treatment.
Summary · context
Additionally, comparisons were made of animals treated with PTH alone, 17alpha-ethynyl estradiol alone, equine estrogens (Premarin) alone, raloxifene alone, or combinations of PTH and equine estrogens or raloxifene.
Report a problemFND-0979447603
04AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, PTH increased axial and appendicular bone mass beyond baseline controls.
In plain wordsIn ovariectomized rats, PTH increased spine and limb bone mass beyond baseline controls.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseAxial and appendicular bone mass versus baseline
Study
Ratn: not reported in source
Ovariectomized osteopenic rats
Comparator
Baseline controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
10 microg/kg · 90 daysAs given in this study (Rat).
Source sentences
Summary
PTH at 10 microg/kg had no effect on body weight or uterine weight, but significantly increased bone mass to beyond those in sham-operated controls, baseline controls, and groups receiving other individual treatments at both axial and appendicular sites.
3 context sentences(design, population, supporting numbers)
Summary · context
The effects of LY353381 x HCl on bones, body weight, and uterine weight were evaluated in 7-month-old rats with osteopenia that was induced by ovariectomizing animals for 1 month before initiation of treatment with several agents individually, in combination, or in sequence.
Summary · context
LY353381 x HCl was administered daily by itself for 90 days, in combination with the amino-terminal fragment of PTH-(1-34) (PTH) for 90 days, or sequentially after PTH when PTH was discontinued after 45 days of treatment.
Summary · context
Additionally, comparisons were made of animals treated with PTH alone, 17alpha-ethynyl estradiol alone, equine estrogens (Premarin) alone, raloxifene alone, or combinations of PTH and equine estrogens or raloxifene.
Report a problemFND-0979447604
05AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, PTH increased axial and appendicular bone mass beyond other individual treatment groups.
In plain wordsIn ovariectomized rats, PTH increased spine and limb bone mass beyond other individual treatments.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseAxial and appendicular bone mass versus other individual treatments
Study
Ratn: not reported in source
Ovariectomized osteopenic rats
Comparator
Other individual treatments
Outcome group
Bone and joint · Musculoskeletal
Studied dose
10 microg/kg · 90 daysAs given in this study (Rat).
Source sentences
Summary
PTH at 10 microg/kg had no effect on body weight or uterine weight, but significantly increased bone mass to beyond those in sham-operated controls, baseline controls, and groups receiving other individual treatments at both axial and appendicular sites.
3 context sentences(design, population, supporting numbers)
Summary · context
The effects of LY353381 x HCl on bones, body weight, and uterine weight were evaluated in 7-month-old rats with osteopenia that was induced by ovariectomizing animals for 1 month before initiation of treatment with several agents individually, in combination, or in sequence.
Summary · context
LY353381 x HCl was administered daily by itself for 90 days, in combination with the amino-terminal fragment of PTH-(1-34) (PTH) for 90 days, or sequentially after PTH when PTH was discontinued after 45 days of treatment.
Summary · context
Additionally, comparisons were made of animals treated with PTH alone, 17alpha-ethynyl estradiol alone, equine estrogens (Premarin) alone, raloxifene alone, or combinations of PTH and equine estrogens or raloxifene.
Report a problemFND-0979447605

Studies that did not test the peptide alone7

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

06AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome
In rats, LY353381 plus PTH increased trabecular bone mass faster and more than PTH alone.
In plain wordsIn rats, LY353381 plus PTH increased spongy bone mass faster and more than PTH alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTrabecular bone mass combination versus PTH
Study
Ratn: not reported in source
Ovariectomized osteopenic rats
Comparator
PTH alone
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
The combination of LY353381 x HCl and PTH increased bone mass at a faster rate and to a greater extent than PTH alone or the combinations of equine estrogens/PTH and raloxifene/PTH at trabecular bone sites.
3 context sentences(design, population, supporting numbers)
Summary · context
The effects of LY353381 x HCl on bones, body weight, and uterine weight were evaluated in 7-month-old rats with osteopenia that was induced by ovariectomizing animals for 1 month before initiation of treatment with several agents individually, in combination, or in sequence.
Summary · context
LY353381 x HCl was administered daily by itself for 90 days, in combination with the amino-terminal fragment of PTH-(1-34) (PTH) for 90 days, or sequentially after PTH when PTH was discontinued after 45 days of treatment.
Summary · context
Additionally, comparisons were made of animals treated with PTH alone, 17alpha-ethynyl estradiol alone, equine estrogens (Premarin) alone, raloxifene alone, or combinations of PTH and equine estrogens or raloxifene.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-0979447606
07AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome
In rats, LY353381 plus PTH increased trabecular bone mass faster and more than equine estrogens plus PTH.
In plain wordsIn rats, LY353381 plus PTH increased spongy bone mass faster and more than equine estrogens plus PTH.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTrabecular bone mass combination versus estrogen combination
Study
Ratn: not reported in source
Ovariectomized osteopenic rats
Comparator
Equine estrogens plus PTH
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
The combination of LY353381 x HCl and PTH increased bone mass at a faster rate and to a greater extent than PTH alone or the combinations of equine estrogens/PTH and raloxifene/PTH at trabecular bone sites.
3 context sentences(design, population, supporting numbers)
Summary · context
The effects of LY353381 x HCl on bones, body weight, and uterine weight were evaluated in 7-month-old rats with osteopenia that was induced by ovariectomizing animals for 1 month before initiation of treatment with several agents individually, in combination, or in sequence.
Summary · context
LY353381 x HCl was administered daily by itself for 90 days, in combination with the amino-terminal fragment of PTH-(1-34) (PTH) for 90 days, or sequentially after PTH when PTH was discontinued after 45 days of treatment.
Summary · context
Additionally, comparisons were made of animals treated with PTH alone, 17alpha-ethynyl estradiol alone, equine estrogens (Premarin) alone, raloxifene alone, or combinations of PTH and equine estrogens or raloxifene.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-0979447607
08AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome
In rats, LY353381 plus PTH increased trabecular bone mass faster and more than raloxifene plus PTH.
In plain wordsIn rats, LY353381 plus PTH increased spongy bone mass faster and more than raloxifene plus PTH.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTrabecular bone mass combination versus raloxifene combination
Study
Ratn: not reported in source
Ovariectomized osteopenic rats
Comparator
Raloxifene plus PTH
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
The combination of LY353381 x HCl and PTH increased bone mass at a faster rate and to a greater extent than PTH alone or the combinations of equine estrogens/PTH and raloxifene/PTH at trabecular bone sites.
3 context sentences(design, population, supporting numbers)
Summary · context
The effects of LY353381 x HCl on bones, body weight, and uterine weight were evaluated in 7-month-old rats with osteopenia that was induced by ovariectomizing animals for 1 month before initiation of treatment with several agents individually, in combination, or in sequence.
Summary · context
LY353381 x HCl was administered daily by itself for 90 days, in combination with the amino-terminal fragment of PTH-(1-34) (PTH) for 90 days, or sequentially after PTH when PTH was discontinued after 45 days of treatment.
Summary · context
Additionally, comparisons were made of animals treated with PTH alone, 17alpha-ethynyl estradiol alone, equine estrogens (Premarin) alone, raloxifene alone, or combinations of PTH and equine estrogens or raloxifene.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-0979447608
09AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome
In rats, LY353381 plus PTH improved cancellous-region bone mass beyond any agent alone.
In plain wordsIn rats, LY353381 plus PTH improved spongy-region bone mass more than any agent alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCancellous bone mass with combination
Study
Ratn: not reported in source
Ovariectomized osteopenic rats
Comparator
Any agent alone
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
The LY353381 x HCl/PTH combination improved bone mass and quality beyond any agent alone in regions enriched for cancellous bone, but was not significantly better than PTH alone on cortical bone.
3 context sentences(design, population, supporting numbers)
Summary · context
The effects of LY353381 x HCl on bones, body weight, and uterine weight were evaluated in 7-month-old rats with osteopenia that was induced by ovariectomizing animals for 1 month before initiation of treatment with several agents individually, in combination, or in sequence.
Summary · context
LY353381 x HCl was administered daily by itself for 90 days, in combination with the amino-terminal fragment of PTH-(1-34) (PTH) for 90 days, or sequentially after PTH when PTH was discontinued after 45 days of treatment.
Summary · context
Additionally, comparisons were made of animals treated with PTH alone, 17alpha-ethynyl estradiol alone, equine estrogens (Premarin) alone, raloxifene alone, or combinations of PTH and equine estrogens or raloxifene.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-0979447609
10AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome
In rats, LY353381 plus PTH improved cancellous-region bone quality beyond any agent alone.
In plain wordsIn rats, LY353381 plus PTH improved spongy-region bone quality more than any agent alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCancellous bone quality with combination
Study
Ratn: not reported in source
Ovariectomized osteopenic rats
Comparator
Any agent alone
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
The LY353381 x HCl/PTH combination improved bone mass and quality beyond any agent alone in regions enriched for cancellous bone, but was not significantly better than PTH alone on cortical bone.
3 context sentences(design, population, supporting numbers)
Summary · context
The effects of LY353381 x HCl on bones, body weight, and uterine weight were evaluated in 7-month-old rats with osteopenia that was induced by ovariectomizing animals for 1 month before initiation of treatment with several agents individually, in combination, or in sequence.
Summary · context
LY353381 x HCl was administered daily by itself for 90 days, in combination with the amino-terminal fragment of PTH-(1-34) (PTH) for 90 days, or sequentially after PTH when PTH was discontinued after 45 days of treatment.
Summary · context
Additionally, comparisons were made of animals treated with PTH alone, 17alpha-ethynyl estradiol alone, equine estrogens (Premarin) alone, raloxifene alone, or combinations of PTH and equine estrogens or raloxifene.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-0979447610
11AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome
In rats, LY353381 plus PTH was not significantly better than PTH alone on cortical bone.
In plain wordsIn rats, LY353381 plus PTH did not significantly improve cortical bone more than PTH alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeCortical bone with combination
Study
Ratn: not reported in source
Ovariectomized osteopenic rats
Comparator
PTH alone
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
The LY353381 x HCl/PTH combination improved bone mass and quality beyond any agent alone in regions enriched for cancellous bone, but was not significantly better than PTH alone on cortical bone.
3 context sentences(design, population, supporting numbers)
Summary · context
The effects of LY353381 x HCl on bones, body weight, and uterine weight were evaluated in 7-month-old rats with osteopenia that was induced by ovariectomizing animals for 1 month before initiation of treatment with several agents individually, in combination, or in sequence.
Summary · context
LY353381 x HCl was administered daily by itself for 90 days, in combination with the amino-terminal fragment of PTH-(1-34) (PTH) for 90 days, or sequentially after PTH when PTH was discontinued after 45 days of treatment.
Summary · context
Additionally, comparisons were made of animals treated with PTH alone, 17alpha-ethynyl estradiol alone, equine estrogens (Premarin) alone, raloxifene alone, or combinations of PTH and equine estrogens or raloxifene.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-0979447611
12AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome
In rats, LY353381 prevented rapid bone loss after PTH withdrawal compared with controls.
In plain wordsIn rats, LY353381 prevented rapid bone loss after PTH stopped compared with controls.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBone maintenance after PTH withdrawal
Study
Ratn: not reported in source
Ovariectomized osteopenic rats
Comparator
Controls after PTH withdrawal
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Additionally, when PTH was discontinued at 45 days, LY353381 x HCl prevented the rapid loss of bone observed in controls.
3 context sentences(design, population, supporting numbers)
Summary · context
The effects of LY353381 x HCl on bones, body weight, and uterine weight were evaluated in 7-month-old rats with osteopenia that was induced by ovariectomizing animals for 1 month before initiation of treatment with several agents individually, in combination, or in sequence.
Summary · context
LY353381 x HCl was administered daily by itself for 90 days, in combination with the amino-terminal fragment of PTH-(1-34) (PTH) for 90 days, or sequentially after PTH when PTH was discontinued after 45 days of treatment.
Summary · context
Additionally, comparisons were made of animals treated with PTH alone, 17alpha-ethynyl estradiol alone, equine estrogens (Premarin) alone, raloxifene alone, or combinations of PTH and equine estrogens or raloxifene.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-0979447612

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.